This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Repros Announces Formation Of Androxal(R) Clinical And Commercial Advisory Board

THE WOODLANDS, Texas, July 9, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced the formation of an international, multi-disciplinary, clinical advisory board to help maximize the commercial opportunity for Androxal.

Management and the Board of Directors of Repros tasked Professor Mike Wyllie, Ph.D., DSc, Director of Repros, and Ron Wiehle, Ph.D., V.P. of Research and Development for Repros, to assemble a well-rounded and effective group of Key Opinion Leaders (KOL's) to begin the multi-disciplinary patient and physician education process that should have great utility for the Company independent of the eventual Androxal commercial strategy.

It has become increasingly obvious that hypogonadism affects many facets of daily living and impacts adversely on patients' quality of life. Correspondingly, treatment has evolved and now involves not just andrologists and urologists, but increasingly, endocrinologists. As with erectile dysfunction, it is anticipated that with the arrival of orally effective therapy, the management of hypogonadism will become the domain of primary care physicians. Primarily the urology and andrology disciplines are to be represented by KOL's at the inaugural advisory board to be held in October 2013, the members of which include:

  • Trinity Bivalacqua, M.D., Ph.D. – Associate Professor of Urology and Oncology, John Hopkins University
  • William Bremner, M.D., Ph.D. – Division of Metabolism, Endocrinology and Nutrition, University of Washington
  • John Dean, M.D. - Immediate past president of the International Society of Sexual Medicine (ISSM), Harley St, London, UK
  • Andre Guay, M.D. – Endocrinology, Diabetes and Metabolism, Lahey Clinic and Boston University
  • Lawrence Hakim, M.D. – Urologist, Cleveland Clinic and incoming president of Sexual Medicine Society of North America
  • Wayne Hellstrom, M.D., F.A.C.S. – Professor of Urology and Chief of Andrology, Tulane University, incoming President of ISSM
  • Edward Kim, Ph.D. – Professor at University of Tennessee Graduate School of Medicine
  • Larry Lipshultz, M.D. - Professor of Urology and Chief of the Division of Male Reproductive Medicine and Surgery at the Baylor College of Medicine
  • Andrew McCullough, M.D. - Professor of Urology/Division of Surgery, Albany Medical College: Urological Institute of North Eastern NY
  • Martin Miner, M.D. – Primary Care Physician with specialties in Hypogonadism, Erectile Dysfunction, Men's Health Center, Miriam Hospital and member of Princeton Guidelines on Cardiovascular Risk committee
  • David Rowland, Ph.D. – Professor of Psychology and Graduate Dean, Valparaiso University
  • Allen Seftel, M.D. – Head of Division of Urology, Cooper University
  • Myles Spar, M.D., M.P.H. – Internal Medicine, Director and Co-Director of Men's Clinic, Akasha Center

In parallel with the formation of this advisory board an additional advisory board comprising primarily endocrinologists and primary care physicians is being assembled over the next several weeks. In the past, the Company has used Glenn Cunningham, M.D., Professor of Medicine and Molecular & Cellular Biology, Baylor College of Medicine, Director, SLEH-BCM Diabetes Program and Nelly Pitteloud, M.D., Professor of Medicine, Co-Chief, Endocrinology, Diabetes and Metabolism Service, CHUV as endocrinology consultants.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,079.57 -42.44 -0.25%
S&P 500 1,996.74 -3.38 -0.17%
NASDAQ 4,557.6950 -11.9260 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs